Cardiomyopathy

Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy

The pharmaceutical company Lexeo Therapeutics has announced positive updates from their phase I/II trial of the gene therapy LX2006 to treat cardiomyopathy in Friedreich’s ataxia (FA). Interim data has shown

Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy Read More »

Researchers identify potential new biomarker of FA disease progression

Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy

Call Us

Email Us

Get Social